Bafna Pharmaceuticals shareholders and shareholding pattern
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Bafna Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008 on BSE, Apr 2018 on NSE
Last close ₹442.75up ₹8.65 (1.99%)BSE ₹449.70
Share price at the NSE close on 27 Oct 2026. Previous close ₹434.10.
27 Oct: open ₹442.75, high ₹442.75, low ₹442.75
52-week range of traded prices to 27 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,047 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 134.52
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 10.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,915
Bafna Pharmaceuticals' shareholding pattern for Sep 2026, filed on 21 Oct 2026, with every filing from Dec 2016: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Bafna Pharmaceuticals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters75.00%
- Foreign institutions9.34%
- Individuals and others15.66%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Individuals and others
| Per cent | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.42% | 33.42% | 33.42% | 33.42% | 33.42% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.40% | 26.40% | 92.64% | 92.64% | 91.74% | 90.39% | 90.40% | 90.42% | 90.42% | 90.12% | 90.00% | 90.02% | 90.00% | 90.00% | 88.74% | 88.43% | 88.30% | 88.30% | 88.30% | 88.30% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | |
| Indian promoters | 33.42% | 33.42% | 33.42% | 33.42% | 33.42% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.36% | 26.40% | 26.40% | 92.64% | 92.64% | 91.74% | 90.39% | 90.40% | 90.42% | 90.42% | 90.12% | 90.00% | 90.02% | 90.00% | 90.00% | 88.74% | 88.43% | 88.30% | 88.30% | 88.30% | 88.30% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 66.58% | 66.58% | 66.58% | 66.58% | 66.58% | 73.64% | 73.64% | 73.64% | 73.64% | 73.64% | 73.64% | 73.64% | 73.64% | 73.60% | 73.60% | 7.36% | 7.36% | 8.26% | 9.61% | 9.60% | 9.58% | 9.58% | 9.88% | 10.00% | 9.98% | 10.00% | 10.00% | 11.26% | 11.57% | 11.70% | 11.70% | 11.70% | 11.70% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% | 25.00% |
| Promoter shares pledgedShare of the promoters' own shares | 8.02% | 29.92% | 29.92% | 51.04% | 51.04% | 65.31% | 65.31% | 65.31% | 51.04% | 32.95% | 51.04% | 51.04% | 51.04% | 50.96% | 50.96% | 1.45% | 1.45% | 1.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Shares in issue | 1,86,56,335 | 1,86,56,335 | 1,86,56,335 | 1,86,56,335 | 1,86,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 23,65,634 | 23,65,634 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 | 2,36,56,335 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 21,12,650 | 30,41,398 | 13,83,108 | – | – | 12,077 | 24,154 | 12,077 | 50,12,077 | 50,12,077 | 50,12,077 | 50,12,077 | 50,00,000 | 5,00,000 | – | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Promoters' shares locked in | 21,12,650 | 30,24,321 | 13,66,031 | – | – | – | – | – | – | – | – | – | – | – | – | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 2,12,90,701 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. Pledged is the share of the promoters' own shares given to lenders as security. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Bafna Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is SRJR LIFESCIENCES LLP, 74.57%. The filing names 2 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| SRJR LIFESCIENCES LLPIndian companies, trusts and others | 74.57% | 1,76,40,016 |
| P PARAS BAFNAIndividuals and Hindu undivided families | 0.21% | 50,000 |
| NAVIN BAFNAIndividuals and Hindu undivided families | 0.18% | 42,015 |
| MAHAVEER CHAND BAFNAIndividuals and Hindu undivided families | 0.03% | 6,338 |
| SASIKALA BAFNAIndividuals and Hindu undivided families | 0.01% | 1,844 |
| AMRI BAI BAFNAIndian companies, trusts and others | 0.01% | 1,989 |
| PARAS BAFNAIndividuals and Hindu undivided families | 0.00% | 49 |
No promoter shares are reported as pledged.
Largest public holders of Bafna Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CULLINAN OPPORTUNITIES FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1Foreign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.21% |
| M7 GLOBAL FUND PCC-CELL DEWCAP FUNDForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.86% | 3.12% | 3.12% | 3.12% | 3.12% | 3.12% | 3.12% |
| ZEAL GLOBAL OPPORTUNITIES FUNDForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.76% | 3.01% | 3.01% | 3.01% | 3.01% | 3.01% | 3.01% |
| ALPANA MUNDRAResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.91% | 3.25% | 3.25% | 3.25% | 3.25% | 2.73% | 2.73% |
| MONARCH NETWORTH FINSERVE PRIVATE LIMITEDCompanies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.40% | 1.40% | 1.35% | 1.35% | 1.35% | – | – | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% | 1.35% |
| GUTTIKONDA VARA LAKSHMIResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.29% | 1.29% | 1.29% | 1.29% | 1.29% |
| M7 GLOBAL FUND PCC-AERIONForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.91% | 3.21% | 3.21% | 3.21% | 3.21% | 3.21% | – |
| MONARCH NETWORTH FINSERVE nPRIVATE LIMITEDCompanies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.35% | 1.35% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ANUSHREE HIMANSHUBHAI SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VRUSHALI HIMANSHU SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | 4.23% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| NISHA JIGNESH MEHTAResident individuals, over ₹2 lakh at face value | 2.95% | 2.95% | 2.95% | 2.95% | 2.95% | – | 2.33% | 2.33% | 2.33% | 2.33% | 2.33% | 2.33% | 2.33% | 2.33% | 2.33% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| P SHOBHAResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.91% | 1.91% | 1.91% | 1.81% | 1.81% | 1.81% | 1.81% | 1.81% | 1.81% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SUBRAMANIAN PResident individuals, over ₹2 lakh at face value | 2.23% | 2.23% | 2.23% | 2.23% | 2.23% | – | 1.76% | 1.76% | – | 1.76% | 1.76% | 1.76% | 1.76% | 1.76% | 1.76% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| NIRAV VIKRAM MANIARResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.69% | 1.69% | 1.69% | 1.69% | 1.69% | 1.69% | 1.69% | 1.69% | 1.69% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| RAMESH KUMAR CHOPRAResident individuals, over ₹2 lakh at face value | 2.05% | 2.05% | 2.05% | 2.05% | 2.05% | – | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| GYANMAL JAINResident individuals, over ₹2 lakh at face value | 1.82% | 1.82% | 1.82% | 1.82% | 1.82% | – | 1.44% | 1.44% | 1.44% | 1.44% | 1.44% | 1.44% | 1.44% | 1.44% | 1.44% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VISHWAS JAINResident individuals, over ₹2 lakh at face value | 1.66% | 1.66% | 1.66% | 1.66% | 1.66% | – | 1.31% | 1.31% | 1.31% | 1.31% | 1.31% | 1.31% | 1.31% | 1.31% | 1.31% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| KUSUM JAINResident individuals, over ₹2 lakh at face value | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | – | 1.28% | 1.28% | 1.28% | 1.28% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| JAISHREE VIKRAM MANIARResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VIKRAM VADILAL MANIARResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VIRAJ SAMIRBHAI SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SAGAR SAMIR SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SAMIR ROHITBHAI SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SHWETA SAMIRBHAI SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SAMIR ROHITKUMAR SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| SWETA SAMIRBHAI SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.06% | 1.06% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VIRAJ SAMEER SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| VIRAJ SAMIR SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| LINDAJEET KAUR RUPRAIOther non-institutions | 3.58% | 3.58% | 3.58% | 3.58% | 3.58% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| DHIRENDRA SOMAIYAOther non-institutions | 1.76% | 1.76% | 1.76% | 1.76% | 1.76% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| KRYPTON INVESTMENT CONSULTANCY PRIVATE LIMITEDOther non-institutions | – | 1.26% | 1.26% | 1.26% | 1.26% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Foreign institutions: CULLINAN OPPORTUNITIES FUND VCC-CULLINAN OPPORTUNITIES INCORPORATED VCC SUB FUND 1 newly named at 3.21%; M7 GLOBAL FUND PCC-AERION no longer named, from 3.21%